EuroBioForum 2013 2nd Annual Conference 27-28 May 2013 - Hilton Munich City, Munich, Germany http://www.eurobioforum.eu/2013 ======================================= # NATIONAL PERSPECTIVES # Switzerland: Personalised medicine in Switzerland under a societal perspective Dr Anne Eckhard Consultant on behalf of the Swiss Academies of Arts and Sciences ======================================= http://www.eurobioforum.eu

1. www.risicare.ch
Personalized Medicine
in Switzerland

2. 2Swiss Academy of Medical Sciences / TA-SWISS
• ambitious concept
• modest response in politics and media so far
• sceptical voices prevail
• «Marketing instrument of the pharmaceutical
industry»
• «We will be the gravediggers of our own
private sphere»
• debate concentrates on special aspects
like genetic testing
Public perception

3. 3Swiss Academy of Medical Sciences / TA-SWISS
• strong privately financed research
• no explicit national programme
• multitude of individual projects
• need for complementing research
• legal aspects
• bioinformatics
• communication
• etc.
Research

4. 4Swiss Academy of Medical Sciences / TA-SWISS
• well established in centres of excellence
for example in university hospitals
• but: even specialists often overtaxed
• personalized medicine:
medicine for the person?
• the boundaries between
«healthy» and «ill» vanish
Medical practice

5. 5Swiss Academy of Medical Sciences / TA-SWISS
• strategy of the
federal administration
• central importance of standardised
electronic medical file
• federalist structure of health system
• niche for private services
• strong need for standardisation
E-Health

6. 6Swiss Academy of Medical Sciences / TA-SWISS
• collection of data
• types of data
• integration in electronic medical file
• open source vs. data protection
• new forms of research (crowd sourcing)
• data processing, data mining
• creating new assets
• area of conflict between
«private» und «public»
Internet and Social Media

7. 7Swiss Academy of Medical Sciences / TA-SWISS
• ban for direct to consumer genetic testing
• different regulations for the dealing with
genetic biomarkers and other biomarkers
• licensing of drugs tailor-made for blockbusters
• from informed consent to
«informed lack of knowledge»?
Legal challenges

8. 8Swiss Academy of Medical Sciences / TA-SWISS
• We are not yet well prepared
for a real breakthrough of personalized medicine
Present situation

9. 9Swiss Academy of Medical Sciences / TA-SWISS
• high potentials
• progress, especially in oncology
• limits of effectiveness
• importance for pharmaceutical industry
• need for action
• information and education
for physicians and patients
• label for physicians with special
competence
• improvements in medical genetics
and the use of case history
• evaluation of direct to customer
services
Position of the Swiss Academy of Medical Sciences

10. 10Swiss Academy of Medical Sciences / TA-SWISS
• strong pharmaceutical and medtech industry
in Switzerland
• need for innovative concepts
• alternative to the blockbuster-model
- with chances and risks
• interest in limiting costs for clinical studies
• new services for new customers
• consequences for political economy
open
Economic aspects

11. 11Swiss Academy of Medical Sciences / TA-SWISS
• obligatory health insurance:
principle of solidarity between the healthy and the ill, younger
and older people, men and women well established
• solidarity in society:
important role of personal responsibility / personal autonomy
decreasing patience with those, who do not care for their
health?
• balance between individual capacities
and individual needs
Concept of solidarity

12. 12Swiss Academy of Medical Sciences / TA-SWISS
• technology assessment
as a catalyst
• intensifying the political
and societal debate
Outlook

13. 13Swiss Academy of Medical Sciences / TA-SWISS
Thank you
for your attention